Sermorelin
Also known as: GRF 1-29 NH2, GHRH 1-29
The original GHRH analog — FDA-studied growth hormone therapy with a long safety record.
Molecular structure image coming soon
Available by prescription through compounding pharmacies. Requires medical supervision and baseline hormone testing.
Overview
Sermorelin is a 29-amino acid peptide analog of Growth Hormone Releasing Hormone (GHRH). It was previously FDA-approved as a diagnostic and therapeutic agent before being withdrawn from the US market in 2002 due to manufacturing changes (not safety concerns). It remains one of the most studied GHRH analogs and is widely used in compounding pharmacy GH optimization protocols.
Mechanism of Action
Sermorelin binds to GHRH receptors in the anterior pituitary, stimulating the synthesis and secretion of growth hormone. Unlike exogenous HGH, sermorelin maintains pituitary feedback loops, resulting in more physiological GH release patterns.
Use Cases
- ✓Age-related growth hormone decline
- ✓Adult growth hormone deficiency
- ✓Body composition improvement
- ✓Sleep quality enhancement
- ✓Immune function support
Research Summary
Sermorelin was studied in multiple FDA-reviewed clinical trials before its withdrawal. Studies demonstrated significant improvements in body composition, sleep quality, and GH levels in adults with GH deficiency. Available through compounding pharmacies under prescriber supervision.
Typical Dosing
200–500 mcg before sleep, subcutaneous injection.
Administration
Prescription Only
Available by prescription through compounding pharmacies. Requires medical supervision and baseline hormone testing.
